Compare USAU & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USAU | CMPX |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.1M | 203.5M |
| IPO Year | 2020 | 2020 |
| Metric | USAU | CMPX |
|---|---|---|
| Price | $13.92 | $0.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 15 |
| Target Price | ★ $26.50 | $5.45 |
| AVG Volume (30 Days) | 132.1K | ★ 5.6M |
| Earning Date | 09-11-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,402,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.23 | $0.89 |
| 52 Week High | $23.72 | $6.88 |
| Indicator | USAU | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 34.74 | 22.99 |
| Support Level | $13.53 | N/A |
| Resistance Level | $16.23 | $2.08 |
| Average True Range (ATR) | 0.48 | 0.10 |
| MACD | -0.18 | -0.02 |
| Stochastic Oscillator | 9.14 | 10.29 |
U.S. Gold Corp is a gold, copper and precious metals development and exploration company pursuing exploration opportunities mainly in Wyoming, Nevada and Idaho. It is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada and the Challis Gold Project in Idaho. The company is engaged in the exploration and evaluation of its mineral properties, which is the single operating segment.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.